α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Pharmacological characterization of the small molecule 03A10 as an inhibitor of α-synuclein aggregation for Parkinson's disease treatment
Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease
Mechanism of Anti-α-Synuclein Immunotherapy
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease
Cellular models of alpha‐synuclein toxicity and aggregation - Delenclos - 2019 - Journal of Neurochemistry - Wiley Online Library
Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease: Trends in Endocrinology & Metabolism
Alpha Synuclein Assay
Novel and rapid device opens new doors for Pa
Current hypotheses for the involvement of a-synuclein in Parkinson's
HTRF Phospho-A-Synuclein Ser129 aggregation
de
por adulto (o preço varia de acordo com o tamanho do grupo)
